Introduction {#Sec1}
============

Bronchiolitis is the leading cause of hospitalization in children aged \<2 years worldwide.^[@CR1]^ The human respiratory syncytial virus (RSV) is the most prevalent etiological agent of bronchiolitis.^[@CR2]^ Even though several risk factors are expected to predispose an individual to severe bronchiolitis, most infants hospitalized with bronchiolitis exhibit no known risk factors that can be associated with the disease.^[@CR2]^ By the age of 2 years, nearly all children have been infected with RSV at least once, yet only 1--3% develop a severe disease requiring hospitalization,^[@CR2],[@CR3]^ suggesting a genetic predisposition to develop a severe disease.^[@CR4]--[@CR9]^ In agreement with this possibility, a twin cohort study revealed a higher concordance in the hospitalization rates of identical twins when compared to fraternal twins, estimating that approximately 20% of the propensity to develop severe bronchiolitis upon RSV infection was attributable to genetic differences.^[@CR10]^ The potential relevance of genetic background to the degree of severity of bronchiolitis is further reinforced by the differences in the rate of RSV hospitalization observed in populations from different racial and ethnic backgrounds living in the same geographic region or country.^[@CR11],[@CR12]^ Together, these findings suggest that host genetic factors might likely contribute to the severity of virus-induced bronchiolitis.

The single-nucleotide polymorphisms (SNPs) rs12979860 and rs8099917 are located near the interleukin 28B (*IL28B*) locus on chromosome 19 and known to affect the expression of *IL28B* mRNA and protein. The expression of IL28B, also known as interferon lambda 3 (IFNλ3), is elevated in individuals with the CC rs12979860 and TT rs8099917 genotype, relative to individuals with an non-CC rs12979860 and non-TT rs8099917 genotype.^[@CR13]--[@CR16]^ Noteworthy also is that CC rs12979860 and TT rs8099917 genotypes are the favorable *IL28B* genotype for hepatitis C virus (HCV) infection as the elevated expression of IL28B is associated with virus clearance, a positive response to therapy, and a better disease outcome.^[@CR17]--[@CR20]^ As IFNλs are the predominant IFNs induced in epithelial cells by respiratory viruses,^[@CR21],[@CR22]^ we were intrigued by the possible association between genetic factors associated with IFNλ3 expression and disease outcome. Thus we designed a prospective cohort study to specifically address whether a link exists between SNPs rs12979860 or rs8099917 and the severity of bronchiolitis in infants.

Materials and methods {#Sec2}
=====================

Patients {#Sec3}
--------

A prospective longitudinal cohort study was performed on 682 previously healthy, full-term infants aged \<2 years admitted at the pediatric units of two tertiary hospitals (Centro Asistencial Doctor Sótero del Río and Hospital Clínico UC-CHRISTUS) and one ambulatory unit (Centro Médico San Joaquín UC-CHRISTUS) in Santiago de Chile during the winter season of years 2014--2016 with a clinical diagnosis of bronchiolitis. Bronchiolitis was defined as an acute lower respiratory tract infection characterized by rhinorrhea, cough, and diffuse wheezes and/or on auscultation.^[@CR23]^ Patients' records were followed until their discharge with all patients receiving standard treatment and fluid management according to clinical guidelines. The length of stay (LOS) in the hospital and Pediatric Intensive Care Unit (PICU) admission, days of oxygen use, the requirement for non-invasive (NIV) or invasive mechanical ventilation (IVM), and mortality were considered in the final outcomes. The criteria used to define clinical severity were based on a previously validated bronchiolitis score system ranging from 0 to 14, which incorporates information such as days of hospitalization, admission to PICU, maximum percentage of fraction of inspired oxygen (FiO~2~), and required number of days of supplementation and mechanical ventilation (Supplemental Table [S1](#MOESM1){ref-type="media"} and ref. ^[@CR24]^). In agreement with ref., ^[@CR24]^ score values lower than seven were defined as "mild" illness (G2 group), while scores of seven and above were considered "severe" cases of bronchiolitis (G1 group). All individuals with comorbidities, including preterm, neuromuscular disease, chronic pulmonary disease, primary and acquired immune deficiency, Down Syndrome, prophylactic use of palivizumab, congenital heart diseases, immigrants, and tourists, were excluded from the study. All patients were evaluated for the presence of atopic comorbidities (atopic dermatitis, allergic rhinitis, food allergies) and other epidemiological variables (birth weight, sex, eutocic or cesarean delivery, and weight at presentation) as suggested in ref. ^[@CR23]^ Clinical data were complemented with a chest X-ray and laboratory analysis. Bacterial infection was suspected when C-reactive protein test was \>10 mg/dl (normal value: 1 mg/dl), the leucocyte count \>20,000 × 10^3^ mm^3^, and based on chest X-ray examination. Parents were requested to answer a questionnaire to enable the identification of any additional epidemiological factor associated with their infants' disease (breastfeeding at 6 months of age, maternal smoking during pregnancy, tobacco exposure at home, parental history of asthma). Blood tests and virus detection were conducted during the first 48 h of hospitalization. Viral agents were identified using the Seeplex RV15 OneStep ACE Detection Kit (Catalog Number: RV6F01Y), designed to detect adenovirus, human RSV (A and B) (RSV), Coronavirus (229E, NL63, OC43) (CoV), human metapneumovirus (hMPV), human rhinovirus (A, B, and C) (hRV), enterovirus (EV), Influenza virus (A and B) (IV), human parainfluenza (1--4) (hPIV), and the human Bocavirus (1--4) (hBoV), according to the manufacturer's instructions. All enrolled patients tested positive for at least one bronchiolitis-associated virus, and all donated an oral swab sample for SNP determination. Scraping was performed on the entire length of inner cheeks with one sterile cotton swab for about 1 min in a circular motion. The swab was placed in a tube containing 300 μl phosphate-buffered saline (137 mM NaCl, 2.7 mM KCl, 4.3 mM Na~2~HPO~4~·7H~2~O, 1.4 mM KH~2~PO~4~, pH 7.4) and genomic DNA was extracted using the QIAamp DNA Mini Kit (Catalog number: 51306). The study was approved by the institutional review board of the Facultad de Medicina de la Pontificia Universidad Católica de Chile (Institutional Review Code: 14-360) and Servicio de Salud Metropolitano Sur Oriente (Resolution Number: 1116) and was conducted according to the Declaration of Helsinki principles. Legal representatives of patients received an explanation of the research and provided written informed consent.

SNP genotyping {#Sec4}
--------------

The distribution of the SNPs rs12979860 and rs8099917 within the Chilean population was determined by us in a previous study.^[@CR25]^ Genotyping of SNPs rs12979860 and rs8099917 was performed as described.^[@CR25]^ The amplification reaction was conducted in a Stratagene Mx3000P thermal cycler (Agilent Technologies, Inc., Santa Clara, CA) and the correct assignment of alleles in each sample was attributed automatically by the MXPro software (Agilent Technologies, Inc.) and manually confirmed by three independent investigators. Positive and negative controls described in ref. ^[@CR25]^ were used in each genotyping assay.

Statistical analysis {#Sec5}
--------------------

Demographic, clinical, and laboratory data are described as frequency (%) for categorical variables and mean (±standard deviation) for quantitative variable data. Odds ratios (ORs) are reported with a 95% confidence interval (CI). Disease outcomes and severity of bronchiolitis were compared among all patients, while the polymorphism frequency was compared between patients and non-infected controls.^[@CR25]^ The clinical symptoms exhibited by patients were analyzed using a two-tailed Fisher exact test for each variable performed in the Statistical Package for the Social Science Software (Version 25, SPSS Inc). The association between polymorphisms and severity of infection was calculated using a two-tailed Fisher exact test with a 2 × 2 contingency table as described elsewhere using the GraphPad (Version 5.1) and OpenEpi (Version 3.01) software as described in ref. ^[@CR25]^ The distribution of Hardy--Weinberg equilibrium (H-WE) was verified by *χ*^2^ test.^[@CR26]^ A Wilcoxon matched-pairs test was used to determine differences between genotype frequencies in the bronchiolitis and control groups. The crude OR values were calculated by univariate analysis using the SPSS V25.0 software package. Differences were considered significant at *p* \< 0.05. Results were confirmed by the SNPstats Web tool (<https://www.snpstats.net/>).^[@CR27]^ The association for each SNP was analyzed in turn with five inheritance models (codominant, dominant, recessive, overdominant, and log-additive). An allele-recessive effect model for rs12979860 and rs8099917 was selected for the final analysis. Data were fitted for the selected covariates (Sex, Hospitalized status, Virus, and Viral coinfection), including one variable of response (Clinical severity). The analysis of association for each SNP was performed with logistic regression analysis summarized with genotype frequencies, proportions, ORs, and 95% CIs. The two SNPs are included in the analysis and linkage disequilibrium (LD) and haplotype analyses were performed. The association analysis of haplotypes was similar to genotypes analysis, using logistic regression (OR and 95% CI). A multivariate stepwise forward and reverse logistic regression analysis was conducted using the SPSS V25.0 software package. Differences were considered significant at *p* \< 0.05.

Results {#Sec6}
=======

Demographic and clinical results {#Sec7}
--------------------------------

A total of 1311 infants diagnosed with bronchiolitis between 2014 and 2016 were evaluated, of which 682 were enrolled. Infants not included in the study had previous comorbidities (*n* = 460), had more than two hospitalizations (*n* = 112), were not available for the study (*n* = 28), were transferred to another hospital (*n* = 12), or declined to sign the consent form (*n* = 17). Among the enrolled infants, 629 showed a single infection by RSV (73.8%), the most commonly detected virus, followed by hMPV (9.5%), hPIV (8.1%), IV (5.7%), hRV (2%), hBoV (0.5%), EV (0.2%), and CoV (0.2%) (Fig. [1](#Fig1){ref-type="fig"}).Fig. 1Flow diagram of the selection of study patients. From 2014 to 2016, 1311 infants with positive viral detection tests consulted at Centro Asistencial Doctor Sótero del Río, Hospital Clínico Red Salud UC CHRISTUS, and Centro Médico San Joaquín Red Salud UC CHRISTUS. Only the first hospitalization was considered for subsequent analysis, which left 682 patients (629 with a single viral infection and 53 with coinfections)

The demographic and clinical features of the 682 infants enrolled in the study are summarized in Table [1](#Tab1){ref-type="table"}. The mean age of patients was 9.2 months, and 396 (58.1%) were boys. Upon recruitment, patients were categorized into two groups (G1 and G2) according to the severity of the respiratory illness at hospital discharge.^[@CR7],[@CR24]^ G1 included 308 (45.2%) infants who presented a severe respiratory disease, while G2 included 374 (54.8%) patients exhibiting mild bronchiolitis. When compared, the two groups showed no significant differences in sex distribution, gestational age, birth weight, type of delivery, nutritional status, maternal pregnancy diseases (preeclampsia, gestational diabetes, hypothyroidism, neurological or another diseases), personal history of atopy, or laboratory findings (Table [1](#Tab1){ref-type="table"} and Supplemental Tables [S2](#MOESM1){ref-type="media"} and [S3](#MOESM1){ref-type="media"}). However, patients in group G1 tended to be younger; to present a lower weight at the time of enrollment; exhibited a significantly higher tobacco exposure risk at home; tended to have parents with a history of asthma; to be more likely to have been admitted to the PICU; to present a clinical bacterial coinfection; to show an elevated use rate of bronchodilators, antibiotics, and systemic corticosteroids; and to require ventilatory support (OR: 17.9 (95% CI: 10.9--29.4)). Patients from G1 also presented atelectasis in findings (OR: 1.9 (95% CI: 1.4--2.9) and opacity (OR: 2.4 (95% CI: 1.6--3.5)) in chest X-ray analysis and had an increased hospital and PICU LOS, increased supplemental oxygen days, and a higher clinical score at the time of medical evaluation at the Emergency Unit (*p* \< 0.001; Table [1](#Tab1){ref-type="table"} and Supplemental Tables [S2](#MOESM1){ref-type="media"} and [S3](#MOESM1){ref-type="media"}). Clinical symptoms that significantly associated with a severe disease were fever, previous history of costal retraction, regular oral tolerance, cyanosis, or apnea. To the physical exam, infants in G1 exhibited a prolonged capillary refill, severe retraction, presence of dehydration, wheezing, crackles, and prolonged expiration relative to infants in G2 (Supplemental Table [S2](#MOESM1){ref-type="media"}).Table 1Demographic and clinical features of the global study subjects with severe and mild bronchiolitisVariablePatients, No. (%)^a^ (*N* = 682)OR (95% CI)*p* ValueSevere disease (*N* = 308)Mild disease (*N* = 374)Age, mean (IQR), months7.9 (0.2--9)10.3 (3--16)\<0.001\*Male sex180 (58.4)216 (57.8)1.0 (0.76--1.39)0.88Gestational age, mean (IQR), weeks38.6 (38--39)38.7 (38--39)0.19Birth weight, mean (SD), g3367.8 (489.2)3355.1 (474.4)0.71Delivery  Eutocic164 (53.2)195 (52.1)1  Cesarean136 (44.2)171 (45.7)0.9 (0.69--1.29) 0.78  Forceps8 (2.6)8 (2.1)1.2 (0.43--3.23) 0.92Maternal pregnancy diseases  Preeclampsia7 (2.3)17 (4.5)0.5 (0.2--1.2)0.16  Diabetes22 (7.1)34 (9.1)0.8 (0.45--1.4)0.53  Hypothyroidism8 (2.6)9 (2.4)1.1 (0.4--2.83)0.99  Epilepsy or neurological disease2 (0.6)2 (0.5)1.2 (0.17--8.7)0.99  Other diseases16 (5.2)22 (5.9)0.9 (0.45--1.7)0.82Weight at presentation, mean (SD), kg7.89 (3.7)9.02 (3.5)\<0.001\*Nutritional status  Undernutrition14 (4.5)19 (5.1)0.9 (0.42--1.76)0.81  Normal216 (70.1)253 (67.6)1  Overweight53 (17.2)77 (20.6)10.8 (0.54--1.2) 0.32  Obesity25 (8.1)25 (6.7)1.2 (0.65--2.1) 0.71Breastfeeding at 6 months of age227 (73.7)269 (71.9)1.2 (0.82--1.6)0.67Maternal smoking during pregnancy60 (19.5)73 (19.5)1.0 (0.69--1.48)0.99Tobacco exposure at home^b^177 (57.5)159 (42.5)1.8 (1.3--2.5)\<0.001\*Parental history of asthma159 (51.6)157 (41.9)1.5 (1.1--2.0)0.01\*Personal history of atopy8 (2.6)10 (2.7)1.0 (0.38--2.52)0.99Treatment for current illness  Bronchodilators307 (99.7)363 (97)9.3 (1.2--72.5)0.015\*  Systemic corticosteroids200 (64.9)145 (38.7)2.9 (2.1--4.0)\<0.001\*  Antibiotics190 (61.7)101 (27)4.4 (3.1--6.0)\<0.001\*Viral coinfections23 (7.5)33 (8.8)0.57Positive cultures  Blood culture2 (0.6)1 (0.2)0.85  Urine culture11 (3.6)10 (2.7)0.64Clinical bacterial coinfection141 (45.8)59 (15.8)4.5 (3.2--6.5)\<0.001\*Hospital length of stay, mean (SD), days9.14 (5.16)3.58 (1.73)\<0.001\*Supplemental oxygen days, mean (SD), days8.04 (5)2.43 (1.59)\<0.001\*PICU admission176 (57.1)30 (8)15.3 (9.9--23.7)\<0.001\*PICU length of stay, mean (SD), days^c^2.63 (3.79)0.05 (0.39)\<0.001\*Days of IVM, mean (SD), days^d^0.42 (2.07)0 (0)\<0.001\*Ventilatory support  NIV133 (43.2)21 (5.6)\<0.001\*  IMV^e^25 (8.1)0 (0)RDAI score, mean (SD)8.8 (3.5)6.82 (3.5)\<0.001\*TAL score, mean (SD)5.2 (1.68)4.1 (1.74)\<0.001\*PRESS score, mean (SD)3.65 (0.97)2.87 (1.34)\<0.001\*PIM-2 score, mean (SD)^c^−4.06 (0.99)−4.28 (0.68)0.001\*Mortality^f^1 (0.3)1 (0.26)1*IQR* interquartile range, *SD* standard deviation, *PICU* pediatric intensive care unit, *NIV* non-invasive mechanical ventilation, *IMV* invasive mechanical ventilation, *RDAI* Respiratory Distress Assessment Instrument, *PRESS* pediatric respiratory severity score, *PIM-2* Pediatric Index Mortality 2\*Significant^a^Data represent no. (%) of patients unless otherwise specified^b^At least one parent smokes^c^Data for 206 patients admitted to PICU^d^Data for 25 patients with invasive mechanical ventilation^e^*p* Value not calculated because one or more boxes contains zero^f^Including 2 died infants with no respiratory reason

Analysis of the *IL28B* SNPs in confirmed bronchiolitis patients {#Sec8}
----------------------------------------------------------------

SNP analysis of the 682 bronchiolitis patients (global) revealed that the frequencies for the rs12979860 CC, CT, and TT genotypes were 0.42, 0.41, and 0.17, while frequencies for the rs8099917 TT, GT, and GG genotypes were 0.51, 0.39, and 0.10, respectively (Fig. [2a](#Fig2){ref-type="fig"}). The allele frequencies for each SNP within the group of bronchiolitis patients were similar to those of the non-infected control cohort, where rs12979860 CC, CT, and TT genotype frequencies were 0.37, 0.44, and 0.19 and rs8099917 TT, GT, and GG genotype frequencies were 0.47, 0.43, and 0.10, respectively.^[@CR25]^ A multiple SNP analysis revealed a positive LD value (*D*' = 0.8893). A direct comparison of SNPs rs12979860 and rs8099917 genotype combinations between the non-infected control cohort and all bronchiolitis patients showed no significant variation in genotype distribution (Fig. [2b](#Fig2){ref-type="fig"}). However, the data do reveal a weighting for homozygote individuals for the major allele (C) in rs12979860 among the ill (Fig. [2b](#Fig2){ref-type="fig"}). Within the control cohort, SNP rs12979860 and rs8099917 genotypes were in H-WE (*χ*^2^ test *p* \> 0.1).^[@CR25]^ In bronchiolitis patients, SNP rs12979860 (*χ*^2^ test 9.7; *p* = 0.005) and rs8099917 (*χ*^2^ test 3.84; *p* = 0.05) genotypes were not in an H-WE, suggesting a possible selection effect most probably associated with the risk of hospitalization. Results further suggest that, when combined, *IL28B* rs12979860/rs8099917 genotypes differ in their correlation with the risk of hospitalization due to bronchiolitis. While not statistically significant, there appears to be a trend toward hospitalization due to bronchiolitis for haplotypes CC/TT and CT/TT when compared to haplotypes TT/GG, TT/TG, and TT/TT (Fig. [2b](#Fig2){ref-type="fig"} and Table [3](#Tab3){ref-type="table"}).Fig. 2*IL28B* single-nucleotide polymorphisms (SNPs) rs12979860 and rs8099917 among the studied population. **a** Distribution of rs12979860 and rs8099917 SNP genotypes among 682 infants with a diagnosis of bronchiolitis. **b** Frequency of the genotype combination for the 2 SNPs rs12979860 and rs8099917 in control population (*n* = 405) and bronchiolitis infants (*n* = 682). The total number of individuals in each group was defined as 100%, and the percentages of individuals with 1 of the 9 possible genotypes were calculated. The numbers within each box correspond to the percentage of individuals with a genotype. Control group data were sourced from ref. ^[@CR25]^

Link between *IL28B* SNPs and the severity of bronchiolitis {#Sec9}
-----------------------------------------------------------

Next, we evaluated whether a link existed between *IL28B* SNPs and the severity of bronchiolitis in the global population of 682 bronchiolitis patients. Analysis of SNP rs12979860 and rs8099917 revealed no correlation with the severity of bronchiolitis for the overall ill population (Fig. [3a, b](#Fig3){ref-type="fig"}). These findings are in full agreements with data reported for an Italian cohort of infants suffering from bronchiolitis.^[@CR28]^ However, infants homozygotes for the minor allele (T) in SNP rs12979860 or homozygotes for the minor allele (G) for SNP rs8099917 were significantly younger and weighed less at the time of hospital admission (Table [2](#Tab2){ref-type="table"}). We, then, stratified our study population by viral coinfection (with vs. without) or hospitalization status (hospitalized vs. non-hospitalized). Results revealed no correlation between the severity of bronchiolitis and viral coinfection but being homozygotes for the minor allele (G) for SNP rs8099917 linked with a mild bronchiolitis among hospitalized patients (OR: 0.55 (95% CI: 0.32--0.95), *p* = 1; Table [3](#Tab3){ref-type="table"}). The effect of the *IL28B* genotype on spontaneous HCV clearance is associated with sex.^[@CR29]--[@CR31]^ So next we stratified our population by sex (male vs. female). Results show that our study population had more boys than girls, suggesting that the first have a 1.4 time higher incidence of bronchiolitis. In boys, we found no evidence of a link between the severity of bronchiolitis and either SNP rs12979860 or SNP rs8099917 (Table [3](#Tab3){ref-type="table"}). However, in girls, being homozygote for the minor alleles, in rs12979860 (T) and in rs8099917 (G), did correlate with mild bronchiolitis (OR: 0.42 (95% CI: 0.20--0.85), *p* = 0.1) and OR: 0.35 (95% CI: 0.14--0.84, *p* = 0.016) (Table [3](#Tab3){ref-type="table"}).Fig. 3Correlation between clinical severity of global bronchiolitis or RSV bronchiolitis and *IL28B* SNPs rs12979860 and rs8099917. **a**, **b** A total of 682 pediatric bronchiolitis patients were grouped according to the SNP rs12979860 (**a**) and rs8099917 (**b**) genotypes and stratified according to the severity of the disease. **c**, **d** A total of 464 pediatric patients diagnosed with RSV bronchiolitis were grouped according to the SNP rs12979860 (**c**) and rs8099917 (**d**) genotypes and stratified according to the severity of the disease. Genotypes were divided into those homozygous for the minor allele (TT rs12979860 and GG rs8099917) and those with heterozygous or homozygous status for the major allele (non-TT rs12979860 and non-GG rs8099917). The total number of patients in each group was defined as 100%, and the severity of the bronchiolitis was evaluated as a dichotomous variable using Fisher exact test. The number within each box corresponds to the percentage of patients with mild or severe diseaseTable 2Frequencies of *IL28B* rs12979860 and rs8099917 SNP in infants hospitalized for global and RSV-bronchiolitisRecessive modelBirth weight (g)Age at hospital admission, (months)Weight at hospital admission (g)Hospital length of stay, (days)PICU length of stay, (days)Supplemental oxygen days (days)Highest oxygen requirement (FiO~2~)Global bronchiolitis (*N* = 682)*IL28B rs12979860*TT3349.5 (495.4)7.69 (2.81)7.93 (2.74)5.69 (3.53)1.05 (2.26)4.65 (3.74)0.3 (0.1)CC+CT3363.1 (479)8.61 (3.46)8.63 (3.1)6.17 (4.8)1.26 (2.97)5.02 (4.72)0.32 (0.13)*p* value0.780.021\*0.046\*0.310.480.420.12*IL28B rs8099917*GG3274.1 (450.55)7.57 (6.28)7.62 (2.5)5.64 (3.4)0.9 (2.14)4.63 (3.34)0.31 (0.11)CG+CC3370.3 (484.2)9.37 (7.2)8.61 (3.47)6.14 (4.73)1.26 (2.93)5 (4.65)0.32 (0.13)*p* value0.120.049\*0.023\*0.40.320.520.33RSV bronchiolitis (*N* = 464)*IL28B rs12979860*TT3314.3 (503)7.76 (6.84)7.66 (2.75)5.99 (3.5)1.18 (2.43)4.89 (3.5)0.3 (0.09)CC+CT3369.5 (490.7)8.79 (7.1)8.24 (3.36)46.4 (4.97)1.38 (3.1)5.35 (4.8)0.33 (0.14)*p* value0.360.220.10.40.60.410.037\**IL28B rs8099917*GG3262.6 (437.5)7.2 (6.4)7.52 (2.6)5.48 (3.1)0.69 (2.05)4.43 (3.1)0.28 (0.07)CG+CC3372.4 (498.2)8.8 (7.1)8.22 (3.34)6.46 (4.9)1.42 (3.1)5.37 (4.48)0.32 (0.13)*p* value0.120.110.130.047\*0.02\*0.15\<0.001\*\*SignificantTable 3Interaction analysis of SNPs rs12979860 and rs8099917 with different covariates in global bronchiolitis populationOutputRecessive modelMild (*N* = 374)Severe (*N* = 308)OR (95% CI)Interaction *p* value*Viral coinfection (adjusted by sex and hospitalization status)* *(N = 682)*SNP rs12979860 NoC/C-C/T2762451.00.5T/T65400.70 (0.46--1.08) YesC/C-C/T26211.0T/T720.39 (00.7--2.14)SNP rs8099917 NoT/T-T/G3012631.00.53G/G40220.62 (0.36--1.08) YesT/T-T/G29221.0G/G410.31 (0.03--2.94)*Hospitalization status (adjusted by sex and viral coinfection)* *(N = 682)*SNP rs12979860 HospitalizedC/C-C/T2922661.01.0T/T68420.66 (0.43-1.01) OutpatientC/C-C/T1001.0T/T401.17SNP rs8099917 HospitalizedT/T-T/G3172851.01.0G/G43230.55 (0.32--0.95) OutpatientT/T-T/G1301.0G/G101.46*Sex (adjusted by hospitalization status and viral coinfection)* *(N = 682)*SNP rs12979860 FemaleC/C-C/T1251161.00.1T/T33120.42 (0.20--0.85) MaleC/C-C/T1771501.0T/T39300.87 (0.51--1.50)SNP rs8099917 FemaleT/T-T/G1351211.00.16G/G2370.35 (0.14--0.84) MaleT/T-T/G1951641.0G/G21160.77 (0.38--1.55)

Correlation of *IL28B* SNPs rs12979860 and rs8099917 with the severity of RSV bronchiolitis {#Sec10}
-------------------------------------------------------------------------------------------

RSV infections (490 total infections) are associated with 72% of all bronchiolitis patients included in this study (Fig. [1](#Fig1){ref-type="fig"}). So next we explored whether there was an observable relationship between SNPs rs12979860 or rs8099917 and the severity of RSV bronchiolitis (464 single-infected patients). The demographic and clinical features of the subgroup of RSV-infected patients are summarized in Table [4](#Tab4){ref-type="table"}. When classified according to the severity of the disease, 218 infants with a single viral infection (46.9%) exhibited severe disease symptoms (G1-RSV) and 246 (53.1%) exhibited mild disease symptoms (G2-RSV). The clinical observations that were significantly different between these groups included fever, cyanosis/apnea, prolonged capillary refill, the magnitude of retractions, and dehydration (Supplementary Table [S4](#MOESM1){ref-type="media"}). Laboratory findings showed a significant difference in bicarbonate levels (*p* = 0.01) between both groups, while chest X-ray analysis showed a difference in the presence of atelectasis (OR: 2.2 (95% CI: 1.4--3.6)) and opacity (OR: 2.5 (95% CI: 1.5--4.1)) (Supplementary Table [S5](#MOESM1){ref-type="media"}). No differences were observed in sex distribution, gestational age, birth weight, type of delivery, nutritional status, maternal pregnancy diseases, and personal history of atopy (Table [4](#Tab4){ref-type="table"}).Table 4Demographic and clinical features of the severe and mild RSV single infection bronchiolitis study subjectsVariablePatients, No. (%)^a^ (*N* = 464)OR (95% CI)*p* ValueSevere disease (*N* = 218)Mild disease (*N* = 246)Age, mean (IQR), months7.1 (0.5--6.4)9.8 (1--7.3)1.2 (0.83--1.75)\<0.001Male sex133 (61)139 (56.5)0.35Gestational age, mean (IQR), weeks38.6 (37--39)38.7 (38--39)0.42Birth weight, mean (SD), g3377.58 (526.1)3346.4 (473.1)0.5Delivery  Eutocic118 (54.1)132 (53.7)1  Cesarean94 (43.1)108 (43.9)0.97 (0.67--1.4)0.48  Forceps6 (2.8)6 (2.4)1.19 (0.35--3.6)0.99Maternal pregnancy diseases  Preeclampsia5 (2.3)10 (4.1)0.6 (0.18--1.6)0.2  Diabetes17 (7.8)24 (9.8)0.78 (0.4--1.5)0.28  Hypothyroidism3 (1.4)4 (1.6)0.8 (0.18--3.8)0.56  Epilepsy or neurological disease2 (0.9)1 (0.4)2.3 (0.2--25.2)0.45  Other diseases14 (6.4)15 (6.1)1.1 (0.49--2.2)0.51Weight at presentation, mean (SD), kg7.48 (2.93)8.69 (3.44)\<0.001Nutritional status  Undernutrition11 (5.0)13 (5.3)0.9 (0.4--2.1)0.5  Normal154 (70.6)167 (67.8)1  Overweight37 (16.9)53 (21.5)0.8 (0.47--1.2)0.15  Obesity16 (7.3)12 (4.9)1.4 (0.7--3.15)0.23Breastfeeding at 6 months of age165 (75.7)183 (74.4)1.1 (0.7--1.6)0.83Maternal smoking during pregnancy38 (17.4)44 (17.9)0.96 (0.6--1.56)0.9Tobacco exposure at home^b^122 (56.0)101 (41)1.8 (1.2--2.64)0.002Parental history of asthma106 (48.6)100 (40.7)1.38 (0.95--1.99)0.09Personal history of atopy1 (0.4)2 (0.8)0.56 (0.05--6.2)0.54Treatment for current illness  Bronchodilators217 (99.5)244 (99.2)1.8 (0.16--19.7)1  Systemic corticosteroids136 (62.4)98 (39.8)2.5 (1.7--3.6)\<0.001  Antibiotics122 (56.0)48 (19.5)5.2 (3.5--7.9)\<0.001Positive cultures  Blood culture2 (0.9)1 (0.4)2.2 (0.2--25)0.45  Urine culture8 (3.7)4 (1.6)2.3 (0.68--7.76)0.14Clinical bacterial coinfection95 (43.6)36 (14.6)4.5 (2.89-7)\<0.001Hospital length of stay, mean (SD), days9.24 (5.32)3.7 (1.6)\<0.001\*Supplemental oxygen days, mean (SD), days8.14 (5.1)2.66 (1.5)\<0.001\*PICU admission127 (58.3)21 (8.5)14.9 (8.87--25.2)\<0.001PICU length of stay, mean (SD), days^c^2.78 (3.86)0.05 (0.33)\<0.001\*Days of IVM, mean (SD), days^d^0.45 (1.66)0 (0)\<0.001\*Ventilatory support  NIV93 (42.7)13 (5.3)\<0.001\*  IMV^e^19 (8.7)0 (0)RDAI score, mean (SD)8.84 (3.64)7.31 (3.4)\<0.001\*TAL score, mean (SD)5.12 (1.76)4.4 (1.6)\<0.001\*PRESS score, mean (SD)3.62 (1.0)3.09 (1.14)\<0.001\*PIM-2 score, mean (SD)^d^−4.03 (1.12)−4.2 (0.52)0.005Mortality^f^1 (0.4)1 (0.4)1.1 (0.07--18.2)1*IQR* interquartile range, *SD* standard deviation, *PICU* pediatric intensive care unit, *NIV* non-invasive mechanical ventilation, *IMV* invasive mechanical ventilation, *RDAI* Respiratory Distress Assessment Instrument, *PRESS* pediatric respiratory severity score, *PIM-2* Pediatric Index Mortality 2\*Significant^a^Data represent no. (%) of patients unless otherwise specified^b^At least one parent smokes^c^Data for 148 patients admitted to PICU^d^Data for 19 patients with invasive mechanical ventilation^e^*p* Value not calculated because one or more boxes contains zero^f^Including 2 died infants for no respiratory reason

SNP analysis of the 464 RSV bronchiolitis patients revealed that the overall frequencies for SNP rs12979860 CC, CT, and TT genotypes were 0.45, 0.38, and 0.17, and for SNP rs8099917 TT, GT, and GG genotypes were 0.53, 0.36, and 0.11, respectively. When compared to the non-infected control population,^[@CR25]^ RSV-infected infants seemed biased toward the combined CC rs12979860--TT rs8099917 haplotype. However, no significant correlation between rs12979860 and bronchiolitis was found (Fig. [3c](#Fig3){ref-type="fig"}), while being homozygote for the minor allele (G) in rs8099917 (50 patients) correlated with mild RSV bronchiolitis (OR: 0.44 (95% CI: 0.24--0.84)) (Fig. [3d](#Fig3){ref-type="fig"}). Consistent with a mild disease, a generally lower supplemental FiO~2~ requirement was observed in infants homozygotes for the minor alleles, in rs12979860 (T) and in rs8099917 (G), during hospitalization. Also, homozygosity for the minor allele in rs8099917 (G) associated with a lower hospitalization and PICU LOS (Table [2](#Tab2){ref-type="table"}). When stratified by sex, no association between SNPs rs12979860 or rs8099917 and the severity of the illness could be established for boys (Table [5](#Tab5){ref-type="table"}). However, for girls, being homozygote for the minor alleles, in rs12979860 (T) (OR: 0.35 (95% CI: 0.14--0.86)) and in rs8099917 (G) (OR: 0.19 (5% CI: 0.05--0.69)), correlated significantly with a mild RSV bronchiolitis (Table [5](#Tab5){ref-type="table"}).Table 5Interaction analysis of SNPs rs12979860 and rs8099917 with sex in RSV-infected populationOutputRecessive modelMild (*N* = 246)Severe (*N* = 218)OR (95% CI)Interaction *p* value*Sex (adjusted by hospitalization status)* *(N = 464)*SNP rs12979860 FemaleC/C-C/T85781.00.056T/T2270.35 (0.14--0.86) MaleC/C-C/T1151101.0T/T24230.99 (0.52--1.87)SNP rs8099917 FemaleT/T-T/G90821.00.1G/G1730.19 (0.05--0.69) MaleT/T-T/G1211211.0G/G18120.63 (0.29--1.36)

Risk factor analysis by using a logistic regression model in RSV bronchiolitis patients {#Sec11}
---------------------------------------------------------------------------------------

To control the potential confounding effects of the various risk factors identified by univariate analysis, a multiple logistic regression model was constructed using the clinical outcome of RSV bronchiolitis as a response variable. The stepwise forward and reverse logistic regression analysis included demographical, clinical, and laboratory variables (age \<6 months, newborn weight \>4 kg, obesity, sex, fever, severe retractions, cyanosis/apnea, capillary refill, dehydration, antibiotics, systemic corticosteroids, chest X-ray findings, tobacco exposure at home, phototherapy, breastfeeding, parental history of asthma, maternal smoking, clinical bacterial coinfection), and TT or GG genotype of *IL28B* SNPs rs12979860 and rs8099917. The clinical outcome of RSV bronchiolitis was dichotomized (mild vs. severe). Table [5](#Tab5){ref-type="table"} summarizes the crude ORs for each variable processed by a univariate logistic regression model and the OR obtained by a multivariate stepwise forward (model 1) and reverse (model 2) logistic regression analysis. Models 1 and 2 show that being \<6 months (*p* \< 0.001), fever (*p* = 0.01), severe retractions (*p* = 0.03), prolonged capillary refill (*p* = 0.02), use of antibiotics (*p* \< 0.001) or systemic corticosteroids (*p* \< 0.001), atelectasis in the chest X-ray (*p* = 0.02), and tobacco exposure at home (*p* = 0.02) associate with a severe RSV bronchiolitis outcome, while the GG genotype in *IL28B* SNP rs8099917 (*p* = 0.002) links with a mild RSV-induced disease.

Discussion {#Sec12}
==========

This study describes the relationship between *IL28B* SNPs rs12979860 and rs8099917 and the severity of bronchiolitis in a population of previously healthy Chilean infants. In spite of a previous study, conducted on a cohort of Italian infants,^[@CR28]^ that suggested no correlation between *IL28B* SNPs rs12979860 and rs8099917 and bronchiolitis, we decided to proceed with this project based on the particular genetic background of the Chilean population. The impact of *IL28B* SNPs among diverse ethnic populations is well documented.^[@CR17],[@CR32]^ The Chilean population, in contrast to the Italian cohort above, is admixed with ancestral contributions from Europe and Native America, as well as Africa.^[@CR33]^ Opposing to what was initially expected, no significant relationship was found between *IL28B* SNPs rs12979860 and rs8099917 and the severity of bronchiolitis when Chilean subjects were categorized based on the severity of the disease (Fig. [3a, b](#Fig3){ref-type="fig"}). Thus, when analyzing the total study population categorized only by disease severity, our findings are in full agreement with the previous study.^[@CR28]^ Importantly, however, in contrast to the preceding study, we extended our analysis by additionally stratifying patients by sex (Table [3](#Tab3){ref-type="table"}). Stratifying by sex alone did not directly link to the severity of bronchiolitis (Tables [1](#Tab1){ref-type="table"} and [6](#Tab6){ref-type="table"}) unless the SNPs are included in the analysis. Results indicate that being homozygote for the minor alleles in rs12979860 (T) and in rs8099917 (G) correlate with a mild disease in girls but not in boys (Table [3](#Tab3){ref-type="table"}). This sex bias was also replicated in the subgroup of RSV bronchiolitis patients (Table [5](#Tab5){ref-type="table"}). The predominance of severe bronchiolitis in boys vs. girls as well a sex bias for other SNPs in bronchiolitis has been previously described by others.^[@CR34]--[@CR36]^ Moreover, the association between SNPs in *IL28B* and sex is also known in the context of an HCV infection.^[@CR29]--[@CR31]^ However, to our knowledge, this study represents the first report to link SNPs in *IL28B* and female sex for bronchiolitis.Table 6Logistic regression of clinical and single-nucleotide polymorphism (SNP) status variables in RSV bronchiolitisVariableCrude ORCI~OR~OR~Model\ 1~ (severe retractions, wheezing, antibiotics, systemic corticosteroids, bacterial coinfection)CI~OR~OR~Model\ 2~CI~OR~Infant aged \<6 months\*1.991.37--2.896.023.36--10.86.023.35--10.79Newborn weight \>4 kg1.20.63--2.29Male sex1.20.83--1.75Female sex1.20.83--1.75Obesity0.890.59--1.36Fever\*1.551.07--2.251.841.13--3.031.851.13--3.03Severe retractions3.021.7--5.362.091.07--4.092.091.07--4.09Cyanosis/apnea\*2.081.19--3.65Prolonged capillary refill\*5.382.53--11.42.821.19--6.712.821.19--6.71Dehydration\*6.851.97--23.7Prolonged expiration1.50.99--2.28Wheezing1.160.8--1.69Antibiotics\*5.243.47--7.933.752.32--6.053.752.32--6.05Systemic corticosteroids\*2.51.72--3.644.072.35--7.054.072.35--7.05Opacity in chest X-ray\*2.51.6--4.13Atelectasis in chest X ray\*2.291.46--3.622.881.67--4.992.891.67--5.0Tobacco exposure at home\*1.821.26--2.641.721.1--2.691.721.1--2.69Maternal smoking during pregnancy0.960.6--1.56Phototherapy1.430.88--2.31Breastfeeding at 6 months of age1.070.7--1.63Family history of asthma\*1.380.96--1.99Clinical bacterial coinfection\*4.52.89--7.0TT genotype rs12979860\*0.690.42--1.15GG genotype rs8099917\*0.440.24--0.840.30.14--0.650.30.14--0.65OR Model 1: stepwise forwardOR Model 2: stepwise reverse\*Significant in the univariate analysis (Table [4](#Tab4){ref-type="table"})

Interestingly, the SNP genotype associated with a lower expression of *IL28B*, non-CC rs12979860 and non-TT rs8099917 genotypes, correlated with a mild bronchiolitis in girls. The precise mechanisms underlying the association between mild bronchiolitis and the *IL28B* genotype in girls are still obscure as this study was not designed to evaluate cytokine expression within the infant population. So, no direct conclusions can be drawn on any association between IL28B expression and disease progression. Nonetheless, the direct correlation between *IL28B* SNPs rs12979860 and rs8099917 and the differential expression of IL28B has been well documented.^[@CR13]--[@CR16]^ Consistent with our observations, a previous report shows that females exhibiting the poorly expressing *IL28B* non-TT rs8099917 genotype clear HCV as efficiently as males with the favorable highly expressing TT rs8099917 genotype.^[@CR31]^ These findings are most probably attributed to known sex-based differences in immunity, which are most evident during the early stages of life.^[@CR37]--[@CR39]^ Thus it is reasonable to suspect that the level of IL28B in girls possessing the TT rs12979860/GG rs8099917 haplotype is sufficient to elicit efficiently response to the viral infection giving rise to a mild bronchiolitis as a final clinical outcome. If so, this would indicate that, in the context of both general and RSV bronchiolitis, the TT rs12979860/GG rs8099917 haplotype is protective in girls. Also, our findings support previous reports which suggest that innate immunity links with the outcome of the diseases induced by respiratory viruses, such as RSV.

In spite of the intriguing possibility raised by this study, which suggests that the host's genetic makeup may play a role in the severity of bronchiolitis, we recognize that the present report has important limitations, primarily sample size. We concede that a larger study is needed to fully confirm the current findings. Also, 72% of all cases included in this study corresponded to RSV bronchiolitis (Fig. [1](#Fig1){ref-type="fig"}). Based on results reported in Table [5](#Tab5){ref-type="table"}, we cannot discard that this factor alone biases our conclusion regarding the general bronchiolitis population (Table [3](#Tab3){ref-type="table"}). The number of bronchiolitis cases associated with other individual viral infection was insufficient to draw any statistically significant alternative conclusion. Furthermore, the study population that was evaluated herein was sourced from two high complexity hospitals, which may have caused selection bias toward severe patients with respiratory distress. This could explain why the CC rs12919860 and TT rs8099917 genotypes were found enriched within ill individuals when compared to the non-infected control population.^[@CR25]^ Finally, this study was focused specifically on the Chilean population, which is genetically distinct from other populations, even when compared with those of other South American neighboring countries.^[@CR32]^ This might limit the generalizability of the findings to other populations with different ancestry composition. Notwithstanding these biases, the results presented herein establish a clear link between female sex, TT rs12979860/GG rs8099917 haplotype, and the clinical severity of RSV bronchiolitis in Chilean pediatric patients.
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